What separates TESA from CJC on your research bench

Tesamorelin (TESA in most community shorthand) and CJC-1295 are both synthetic analogs of GHRH, growth hormone-releasing hormone. GHRH is the signal that tells the pituitary gland to pulse out growth hormone. Both compounds bind the GHRH receptor. From that high level they look like close substitutes. On the bench, they behave differently in ways that matter to your data.

Tesamorelin mirrors the full 44-amino-acid GHRH sequence, with a trans-3-hexenoic acid group attached to the N-terminus (the starting end of the chain) to block a specific enzyme called DPP-IV from cleaving it immediately. That modification is why tesamorelin reached clinical-grade manufacturing and has a published half-life of roughly 26 minutes.

CJC-1295 is built from just the first 29 amino acids of GHRH, the active core sometimes sold separately as Modified GRF 1-29 or Mod GRF 1-29. It carries four amino acid substitutions that resist enzymatic degradation. On its own, Mod GRF 1-29 has a half-life in the same general range as tesamorelin. CJC-1295 with DAC adds a lysine-maleimide linker that lets the peptide bind albumin (a protein that acts as a molecular carrier), extending the half-life to several days. These are two very different compounds that share a name, and sourcing mixups are common.

Why Ipamorelin Pairs With Either

Ipamorelin (IPA) is a synthetic pentapeptide, a chain of just five amino acids. It works on an entirely different receptor called the ghrelin receptor (GHSR, for growth hormone secretagogue receptor). Because GHRH analogs and ghrelin-pathway agonists act through separate mechanisms, the combination produces a larger GH signal in research models than either compound alone. That is the reason TESA+IPA and CJC+IPA both appear in the literature and both circulate in the research community.

Ipamorelin is notably selective. It does not strongly stimulate cortisol or prolactin release the way that older GHRPs like GHRP-6 do. When you want a cleaner signal from the GH axis without hormonal noise from those pathways, that selectivity matters for interpreting your results.

A practical note: ipamorelin is a separate vial and a separate reconstitution. Some researchers combine them into a single vial after both powders are dissolved. Others keep them separate and mix at the point of use. Combining saves a pipetting step; keeping them separate lets you adjust one concentration without discarding the other. Both approaches appear in active protocols.

What Happens to Your Vials After Reconstitution

Both TESA and CJC are shipped as lyophilized powder, which is freeze-dried and stable at or below room temperature within the supplier's stated shelf life. Once you add diluent, the stability window shrinks considerably.

Bacteriostatic water, sterile water containing 0.9% benzyl alcohol as a preservative, is the standard diluent for both compounds. The benzyl alcohol inhibits bacterial growth across repeated vial punctures. Plain sterile water for injection works for single-use vials but offers no protection once you enter the vial a second time. Avoid any water with variable mineral content; pH swings accelerate hydrolysis, the chemical process where water molecules split apart the peptide bonds holding your compound together.

Glass also matters. Peptides adsorb to plastic surfaces at low concentrations, meaning measurable amounts of your sample bind to the vial wall and never reach your pipette. Borosilicate glass vials and glass cartridges reduce that surface loss significantly. If your working concentration is already low, adsorption is a real source of error in your downstream measurements.

• Store reconstituted peptides at 2 to 8 degrees Celsius.
• Limit freeze-thaw cycles. Each cycle risks aggregation, where peptide molecules clump into inactive forms.
• Shield vials from light; UV exposure oxidizes certain amino acid side chains.
• Label the reconstitution date. Most researchers treat reconstituted GHRH peptides as reliable for around four weeks refrigerated in bacteriostatic water, and replace them if cloudiness or precipitation appears.

Running the Math for Two Compounds at Once

TESA+IPA and CJC+IPA both require two separate reconstitution calculations. Each compound has its own molecular weight, its own vial quantity, and potentially its own target concentration for your protocol. A common mistake is copying the same volume and dilution figure across both vials without adjusting for those differences.

The framework is simple: divide the mass of peptide in the vial by the volume of diluent you add to get your stock concentration. If you add 2.5 mL to a 5 mg vial, your stock is 2 mg/mL. Pull 0.1 mL and you are working with 0.2 mg. Do that calculation independently for each compound, because ipamorelin's vial quantity may be completely different from your TESA or CJC vial.

Purity affects that math directly. A peptide at 95% HPLC purity (a common research-grade minimum) means 5% of the mass you weighed is not your target compound. Suppliers who invest in a second or third purification pass push that number higher, and your concentration estimates become more accurate. Ask for a certificate of analysis that includes both HPLC purity and mass spectrometry data confirming the correct molecular weight. That documentation is the clearest evidence you reconstituted the right compound at the concentration you calculated.

Related from our lab: the pen · cartridges · bacteriostatic water · reconstitution calculators

Shared by PreppinPeppers for research, educational, and demonstration awareness only. We link to third-party coverage; we do not endorse it, and nothing here is medical advice or a recommendation to use any substance in humans or animals. Our products are sold for laboratory research use only.

Frequently asked questions

What is the difference between CJC-1295 with DAC and CJC-1295 without DAC?

CJC-1295 without DAC (Mod GRF 1-29) has a short half-life comparable to tesamorelin. The DAC variant adds a lysine-maleimide linker enabling reversible albumin binding, extending half-life to several days, making them functionally distinct for research protocol design.

Why is ipamorelin paired with GHRH analogs like tesamorelin or CJC-1295 in research?

Ipamorelin acts on the ghrelin receptor (GHSR), separate from the GHRH receptor. The dual-pathway combination produces a larger GH pulse in research models than either compound alone, and ipamorelin's selectivity avoids cortisol and prolactin signal interference.

How should reconstituted GHRH peptides be stored in a laboratory setting?

Use bacteriostatic water as diluent, store at 2-8 °C in borosilicate glass vials, minimize freeze-thaw cycles to prevent aggregation, shield from UV light to prevent side-chain oxidation, and label the reconstitution date to track the working solution's age.

More in our bacteriostatic water and diluents collection.

What the research community gets wrong about tesamorelin versus CJC-1295

These two GHRH analogs get treated as interchangeable in a lot of bench chatter. On paper they both bind the GHRH receptor, but the details that change your handling and your data get lost. Here are the mixups worth catching.

• "CJC-1295" is not one thing. The version with DAC carries a lysine-maleimide linker that binds albumin and stretches the half-life to several days. The version without DAC (often labeled Mod GRF 1-29) has a short half-life closer to tesamorelin. Two vials can wear the same name and behave nothing alike, so read the certificate of analysis, not just the label.
• Sharing a receptor does not make them structural twins. Tesamorelin mirrors the full 44 amino acid GHRH chain with an N-terminal group that blocks the DPP-IV enzyme. CJC-1295 is built from only the first 29 amino acids with substitutions. Different sequence, different mass, different molecular weight to plug into your dilution math.
• Ipamorelin is not a GHRH analog. It is a five amino acid peptide that works on the ghrelin receptor (GHSR), a separate pathway. Lumping it in with tesamorelin or CJC-1295 hides why the pairing produces a bigger signal in research models: the two compounds act through different receptors.
• One reconstitution volume does not cover both vials. Each compound has its own vial quantity and its own molecular weight, so copying the same diluent volume and dilution factor across both gives you the wrong stock concentration for at least one of them. Run the mass-divided-by-volume math separately for each vial.
• Powder stability is not solution stability. Lyophilized powder is stable within the supplier shelf life, but once you add diluent the window shrinks to weeks in the fridge. Treating a reconstituted vial like it keeps as long as the sealed powder is how samples quietly lose potency before you notice cloudiness.

From our bench: If you have reconstituted tesamorelin and CJC-1295 side by side, we want your real observations. Did one solution turn cloudy or throw a visible precipitate before the other under the same fridge storage? Did glass versus plastic vials change how much sample you could recover at low working concentrations? Tell us what you measured and how you stored the vials, with no rounded-up numbers, and we will add verified bench notes to this guide.

Sources

1. Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
2. Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
3. Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
4. PubChem: Tesamorelin (CID 16137828), GHRH analog, molecular formula and identifiers
5. PubChem: CJC-1295 (CID 91971820), structure and identifiers
6. FDA / DailyMed: Tesamorelin (EGRIFTA) prescribing labels, Theratechnologies Inc.